BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30230537)

  • 1. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup.
    Johann PD; Bens S; Oyen F; Wagener R; Giannini C; Perry A; Raisanen JM; Reis GF; Nobusawa S; Arita K; Felsberg J; Reifenberger G; Agaimy A; Buslei R; Capper D; Pfister SM; Schneppenheim R; Siebert R; Frühwald MC; Paulus W; Kool M; Hasselblatt M
    Am J Surg Pathol; 2018 Apr; 42(4):506-511. PubMed ID: 29324471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
    Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
    J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
    Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
    J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
    Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.
    Johann PD; Hovestadt V; Thomas C; Jeibmann A; Heß K; Bens S; Oyen F; Hawkins C; Pierson CR; Aldape K; Kim SP; Widing E; Sumerauer D; Hauser P; van Landeghem F; Ryzhova M; Korshunov A; Capper D; Jones DTW; Pfister SM; Schneppenheim R; Siebert R; Paulus W; Frühwald MC; Kool M; Hasselblatt M
    Brain Pathol; 2017 Jul; 27(4):411-418. PubMed ID: 27380723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors.
    Pathak R; Zin F; Thomas C; Bens S; Gayden T; Karamchandani J; Dudley RW; Nemes K; Johann PD; Oyen F; Kordes U; Jabado N; Siebert R; Paulus W; Kool M; Frühwald MC; Albrecht S; Kalpana GV; Hasselblatt M
    Acta Neuropathol; 2021 Aug; 142(2):361-374. PubMed ID: 34003336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors.
    Jeibmann A; Schulz J; Eikmeier K; Johann PD; Thiel K; Tegeder I; Ambrée O; Frühwald MC; Pfister SM; Kool M; Paulus W; Hasselblatt M
    J Neurooncol; 2017 Feb; 131(3):477-484. PubMed ID: 28108836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of a new oncogenic mechanism for atypical teratoid rhabdoid tumors in patients with ring chromosome 22.
    Byers HM; Adam MP; LaCroix A; Leary SE; Cole B; Dobyns WB; Mefford HC
    Am J Med Genet A; 2017 Jan; 173(1):245-249. PubMed ID: 27734605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MYC by the SMARCB1 tumor suppressor.
    Weissmiller AM; Wang J; Lorey SL; Howard GC; Martinez E; Liu Q; Tansey WP
    Nat Commun; 2019 May; 10(1):2014. PubMed ID: 31043611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.
    Erkek S; Johann PD; Finetti MA; Drosos Y; Chou HC; Zapatka M; Sturm D; Jones DTW; Korshunov A; Rhyzova M; Wolf S; Mallm JP; Beck K; Witt O; Kulozik AE; Frühwald MC; Northcott PA; Korbel JO; Lichter P; Eils R; Gajjar A; Roberts CWM; Williamson D; Hasselblatt M; Chavez L; Pfister SM; Kool M
    Cancer Cell; 2019 Jan; 35(1):95-110.e8. PubMed ID: 30595504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical teratoid rhabdoid tumor in a child with neurofibromatosis type 2: A novel dual diagnosis.
    Kotch C; Fisher MJ; Lin F; Zhong Y; Gallo D; Fan Z; Chen J; Santi M; Li MM
    Cancer Genet; 2022 Apr; 262-263():1-4. PubMed ID: 34972035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous Regression of Atypical Teratoid Rhabdoid Tumor Without Therapy in a Patient With Uncommon Regional Inactivation of SMARCB1 ( hSNF5/INI1).
    Peterson JEG; Bavle A; Mehta VP; Rauch RA; Whitehead WE; Mohila CA; Su JM; Adesina AM
    Pediatr Dev Pathol; 2019; 22(2):161-165. PubMed ID: 30470167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort.
    Benesch M; Nemes K; Neumayer P; Hasselblatt M; Timmermann B; Bison B; Ebetsberger-Dachs G; Bourdeaut F; Dufour C; Biassoni V; Morales La Madrid A; Entz-Werle N; Laithier V; Quehenberger F; Weis S; Sumerauer D; Siebert R; Bens S; Schneppenheim R; Kool M; Modena P; Fouyssac F; C Frühwald M
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28022. PubMed ID: 31571386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Teratoid/Rhabdoid Tumor: Revisiting Histomorphology and Immunohistochemistry With Analysis of Cyclin D1 Overexpression and
    Sali AP; Epari S; Nagaraj TS; Sahay A; Chinnaswamy G; Shetty P; Moiyadi A; Gupta T
    Int J Surg Pathol; 2021 Apr; 29(2):155-164. PubMed ID: 32703045
    [No Abstract]   [Full Text] [Related]  

  • 16. Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor: A FISH and Immunohistochemical Comparison.
    Pacheco MC; Dolan M; Bendel A
    Pediatr Dev Pathol; 2017; 20(5):381-386. PubMed ID: 28382842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities.
    Paassen I; Williams J; Ríos Arceo C; Ringnalda F; Mercer KS; Buhl JL; Moreno N; Federico A; Franke NE; Kranendonk M; Upadhyaya SA; Kerl K; van de Wetering M; Clevers H; Kool M; Hoving EW; Roussel MF; Drost J
    Oncogene; 2023 May; 42(20):1661-1671. PubMed ID: 37020038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description.
    Barresi V; Lionti S; Raso A; Esposito F; Cannavò S; Angileri FF
    Neuropathology; 2018 Jun; 38(3):260-267. PubMed ID: 29110337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
    Darr J; Klochendler A; Isaac S; Eden A
    Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
    Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
    Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.